Orphidis Pharma is a Singapore-based pharmaceutical company partnering with biotechnology and pharmaceutical manufacturers to bring innovative specialist medicines to patients across Asia.
From managed access and named-patient programmes to registration, launch and long-term commercialisation, we provide one accountable regional relationship combining central commercial leadership with locally adapted execution.
A future where access to innovative specialist medicines does not depend on where in Asia a patient lives
To help pharmaceutical and biotechnology companies bring innovative rare disease, oncology and specialty medicines to patients across Asia sooner, with the focus, compliance and local understanding each market demands
That belief is why I co-founded Orphidis. Across Asia, patients face very different routes to diagnosis, funding and treatment, and many innovative medicines reach certain markets years later than others, or not at all.
We work with pharmaceutical and biotechnology companies to close that gap, whether through managed access, registration or long-term commercialisation.
By combining local market understanding, rigorous compliance and focused execution, we aim to bring innovation closer to the patients who need it.
Whether you are considering managed access, registration or a broader regional commercial partnership, we’d welcome a conversation